Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Pituitary Disorders
•
General Endocrinology
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
Related Questions
Does norethindrone suppress FSH, LH completely?
When do you recommend the use of oral testosterone replacement over injectable testosterone?
Should oral combined contraceptives be held prior to overnight dexamethasone suppression test to rule out Cushings?
For patients with central hypothyroidism and a clear etiology (such as recent head irradiation), do you recommend brain imaging prior to starting thyroid hormone replacement therapy?
Does growth hormone (GH) replacement therapy reduce the risk of fractures in patients with GH deficiency?
When and how do you taper off cabergoline therapy for treatment of microprolactinoma?
Would you order a fibroscan to screen for MASLD in patients with insulin resistance but normal LFTs?
Given the new 2022 WHO classification of pituitary tumors, should we be regularly counseling our patients about the risk of malignancy for what we previously referred to as pituitary adenomas but now classified as pituitary neuroendocrine tumors (PitNETs)?
Is bilateral oophorectomy the first-line treatment for ovarian hyperthecosis?
What is your approach to differentiating diabetes insipidus from primary polydipsia in the outpatient setting?
